Fibrinolytic therapy in left side-prosthetic valve acute thrombosis. In depth systematic review

Reyes-Cerezo, Esteban; Jerjes-Sánchez, Carlos; Archondo-Arce, Tamara; García-Sosa, Anabel; Garza-Ruiz, Ángel; Ramírez-Rivera, Alicia; Ibarra-Pérez, Carlos
July 2008
Archivos de Cardiología de México;jul-sep2008, Vol. 78 Issue 3, p309
Academic Journal
Background: Limited data are available on the impact and safety of fibrinolytic therapy (FT) in left -- side prosthetic valve acute thrombosis (PVAT). Study objective: To improve our knowledge about the FT role in left --side PVAT. Design: Bibliographic search and analysis. Methods: MEDLINE search from January 1970 to January 2007. Studies were classified according to the evidence level recommendations of the American College of Chest Physicians and included if they had objective diagnosis of left-side PAVT and FT efficacy assessment (hemodynamic, echocardiographic or fluoroscopic improvement). New York Heart Association class was used to establish functional state. Data on clinical characteristics, diagnosis strategy, anticoagulation status, fibrinolytic and heparin regimens, cardiovascular adverse events, outcome, and follow-up were also required. Results: A systematic search produced a total of 900 references. Each abstract was analyzed according to the predetermined criteria. Thirty-two references with 904 patients constitute the subject of this analysis. Only one trial had evidence III and thirty-one evidence V. FT was more used in young female patients (64%) with prosthetic mitral valve thrombosis (77%), and clinical instability (82%). Transesophageal echocardiogram had a higher thrombus detection rate (100%). Although several fibrinolytic regimens were used in a first or second course, streptokinase was the most frequent agent (61%). Clinical improvement was observed in 86% of the patients, objective success in 78%, and failure in 14%. Rescue fibrinolysis was done in 17%. Complications: peripheral and cerebral embolism rate was 5% and 4%, respectively. Major bleeding 4% and intracranial hemorrhage 1%. Conclusions: The available evidence demonstrates that in PVAT fibrinolytic therapy improves the outcome in younger, more ill patients, especially females, independently of the fibrinolytic regimen used with a low complications rate.


Related Articles

  • Prosthetic Valve Thrombosis -- Urgent Surgery or Thrombolysis? Boyle, Andrew J. // Clinical Cardiology Alert;Mar2011, Vol. 30 Issue 3, p21 

    In this article the author discusses a study by S. Keulerrs and colleagues which revealed thrombolysis as a viable alternative to emergency surgery in the treatment of prosthetic valve thrombosis (PVT). He highlights the high risk of complications with both treatments, and the high morbidity and...

  • Prosthetic Tricuspid Valve Thrombosis: Three Case Reports and Literature Review. Yaminisharif, Ahmad; Javad Alemzadeh-Ansari, Mohammad; Hossein Ahmadi, Seyed // Journal of Tehran University Heart Center;2012, Vol. 7 Issue 4, p147 

    A common complication of prosthetic heart valves is thrombosis. Although the incidence of prosthetic valve thrombosis (PVT) in the tricuspid position is high, there are not enough data on the management of it, in contrast to left-sided PVT. Here, we describe three cases of tricuspid PVT with...

  • Thrombolysis for Valve Prosthesis. Kistler, Peter; Zentner, Dominica; Morgan, John G.; Grigg, Leanne E. // Heart, Lung & Circulation;Mar2003, Vol. 12 Issue 1, p75 

    Studies the use of thrombolysis for heart valve prosthesis. Observation of tricuspid valve stenosis on echocardiography; Analysis of mechanical valve implanted in a 48-year-old former intravenous drug user.

  • Batten Down the Hatches for Changes to LV Pacing, Thrombectomy, and More.  // Cardiology Coding Alert;Nov2012, Vol. 15 Issue 11, p83 

    The article provides current procedural terminology (CPT) 2013 updates for cardiology procedures. Revision in codes for several procedures is provided including Left Ventricular pacing, Fluid removal from chest, Catheter introduction, Cervical, cerebral, and carotid angiography, Transcatheter...

  • Heparin.  // Reactions Weekly;Aug2015, Vol. 1564 Issue 1, p100 

    The article presents case studies of five pregnant women who were diagnosed with mechanical valve thrombosis (MVT) while receiving anticoagulant therapy with heparin following a mechanical heart valve prosthesis implantation.

  • Surgery for prosthetic valve obstruction. A single center study of 136 patients Roudaut, Raymond; Roques, Xavier; Lafitte, Stéphane; Choukroun, Emmanuel; Laborde, Nadine; Madona, Francesco; Deville, Claude; Baudet, Eugène // European Journal of Cardio-Thoracic Surgery;Dec2003, Vol. 24 Issue 6, p868 

    Objectives: Prosthetic heart valve obstruction (PHVO) is a potentially fatal complication of heart valve replacement with mechanical substitute mainly due to thrombosis. The purpose of this report is to present a single-center experience of 136 consecutive patients operated on between 1978 and...

  • Coronary Artery Embolism Causing Acute Myocardial Infarction in Patients with Mechanical Heart Valve Prosthesis: Which is the Optimal Treatment? Tang, Liang; Hu, Xin-qun; Zhou, Sheng-hua // Heart, Lung & Circulation;May2014, Vol. 23 Issue 5, p422 

    Objective: Coronary artery embolism resulting in acute myocardial infarction (AMI) is an infrequent but potentially life-threatening occurrence. To date, there is still no consensus in the literature regarding the optimal therapeutic algorithm for embolic myocardial infarction. Patients: We...

  • Thrombosis of A Prosthetic Mitral Valve After Withdrawal of Phenprocoumon Therapy. Wilke, Andreas; Wende, Christian M.; Horst, Michael; Steverding, Dietmar // Cardiology Research;2011, Vol. 2 Issue 6, p298 

    Patients with prosthetic heart valves require lifelong oral anticoagulant therapy based on vitamin K antagonists. These patients may need interruption of their anticoagulant therapy if they have to undergo surgery. The clinical challenge is to identify patients who can safely undergo surgery...

  • Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. Greiten, Lawrence E.; McKellar, Stephen H.; Rysavy, Joseph; Schaff, Hartzell V. // European Journal of Cardio-Thoracic Surgery;May2014, Vol. 45 Issue 5, p914 

    OBJECTIVES Warfarin is used to reduce the risk of stroke and thromboembolic complications in patients with mechanical heart valves. Yet, despite frequent blood testing, its poor pharmacokinetic and pharmacodynamic profiles often result in variable therapeutic levels. Rivaroxaban is a direct...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics